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Synopsis  33 
Background 34 
The need for antifungal stewardship is gaining recognition with increasing incidence of invasive 35 
fungal infection (IFI) and antifungal resistance alongside the high cost of antifungal drugs. Following 36 
an audit showing suboptimal practice we initiated an antifungal stewardship program and 37 
prospectively evaluated its impact on clinical and financial outcomes. 38 
 39 
Patients and Methods 40 
From October 2010 to September 2016, adult inpatients receiving amphotericin B, echinocandins, 41 
intravenous (IV) fluconazole, flucytosine or voriconazole were reviewed weekly by an Infectious 42 
Diseases Consultant and Antimicrobial Pharmacist. Demographics, diagnosis by EORTC criteria, drug, 43 
indication, advice, acceptance, and in-hospital mortality were recorded. Antifungal consumption and 44 
expenditure and candidaemia species and susceptibility data were extracted from pharmacy and 45 
microbiology databases.  46 
 47 
Results 48 
A total of 432 patients were reviewed, most commonly receiving AmBisome® (35%) or IV fluconazole 49 
(29%). Empiric treatment was often unnecessary, with 82% having no evidence of IFI. Advice was 50 
given in 64% of reviews (most commonly de-escalating or stopping treatment) and was followed in 51 
84%. Annual antifungal expenditure initially reduced by 30% (£0.98 to £0.73million), then increased 52 
to 20% above baseline over a 5-year period; a significantly lower rise compared to national figures 53 
showing doubling of expenditure over the same period. Inpatient mortality, Candida species 54 
distribution and rates of resistance were not adversely affected by the intervention. 55 
 56 
Conclusion 57 
Provision of specialist input to optimise antifungal prescribing, resulted in significant cost savings 58 
without compromising on microbiologic or clinical outcomes. Our model is readily implementable by 59 
hospitals with high numbers of at risk patients and antifungal expenditure. 60 
  61 
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Background  62 
 63 
Stewardship programs are effective in reducing inappropriate antimicrobial use, improving patient 64 
outcome and limiting emergence of resistance.
1,2
 Due to the higher burden of bacterial infection, 65 
health policy has traditionally emphasised curtailing antibiotic resistance3 and spread of hospital-66 
acquired Clostridium difficile 
4
 and MRSA.
5
 To date, implementation and evaluation of stewardship 67 
programs has therefore largely focused on antibacterials.6,7 68 
 69 
The complexity of managing invasive fungal infection (IFI) poses a challenge to antifungal 70 
stewardship (AFS). The number of ‘high risk’ immunosuppressed hosts is growing which, coupled 71 
with poor local diagnostics and inadequate prescriber knowledge of IFI, results in high rates of 72 
inappropriate prescribing (25-75% of prescriptions).8-11 This offers scope for specialist intervention.  73 
Stewardship may also help stem the emergence of antifungal resistance,
3,6,12
 which poses an 74 
increasing threat to global food security and human health.13  75 
 76 
An audit of antifungal prescribing at our hospital in 2009 identified suboptimal post-prescription 77 
review and performance of azole therapeutic drug monitoring (TDM). Following the appointment of 78 
a consultant infectious diseases physician with an interest in IFI we implemented weekly AFS rounds 79 
commencing October 2010. Our aims were to optimise care of patients with IFI; stop unnecessary 80 
empiric treatment; de-escalate antifungal therapy where possible; perform TDM appropriately; and 81 
reduce antifungal usage and expenditure, without compromising clinical outcomes or resistance 82 
rates.  83 
 84 
To our knowledge, ours was the first dedicated AFS program introduced in England. Six years later, 85 
just 11% (5/47) of English acute NHS Trusts surveyed reported undertaking dedicated AFS.
7
 Only a 86 
handful of reports on the effectiveness of AFS programs in the USA and Europe have been published 87 
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to date.
14-19
 A single report from a tertiary UK centre demonstrated a crude saving of £188,000 in 88 
drug costs over a 1-year intervention period in 173 patients.20 We present an evaluation of the 89 
effectiveness of our AFS programme (2010-16) based on comprehensive, prospectively collected 90 
clinical, microbiologic and financial outcome data.  91 
 92 
Patients and Methods  93 
Ethics 94 
In keeping with St Georges Hospital Ethics Committee policy and guidance from the National 95 
Research Ethics Committee21 no formal ethical approval was considered necessary as this was an 96 
audit of data collected during routine clinical activities. 97 
 98 
Setting 99 
St George's Hospital is a 1300-bed teaching hospital in Southwest London providing secondary care 100 
to 0.5 million people and tertiary care services to 3.4 million people in Southeast England. These 101 
include populations at risk of IFI: patients with acute leukaemia, autologous and allogenenic stem 102 
cell transplant (n=29/year in 2009, rising to 53 in 2016), renal dialysis and transplant, inpatients in an 103 
18-bedded Infectious Diseases ward (admitting 100-120 HIV-infected patients p.a.) and 3 adult 104 
Intensive Care Units (General, Cardiothoracic and Neurosurgical: total bed expansion from 39 to 60 105 
between 2010 and 2016). There is an Infectious Diseases consult service for all inpatients with 106 
suspected or proven infection and those on ICU. On site IFI diagnostics include Candida speciation 107 
and fluconazole susceptibility testing, Pneumocystis immunofluorescence (latterly PCR), twice 108 
weekly azole TDM, same day HRCT Chest, and histopathology with fungal-specific stains (Grocott/ 109 
PAS). Biomarkers (galactomannan, beta-D-glucan), fungal serology and PCR, mould identification and 110 
susceptibility are sent away to the National reference laboratory in Bristol. 111 
 112 
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AFS strategies in place prior to initiation of stewardship rounds were Antifungal Guidelines (since 113 
2005, updated annually) and formulary restriction (Microbiology /Infectious Diseases authorisation 114 
for off-guideline use of amphotericin, echinocandins, posaconazole and voriconazole since 2008). 115 
 116 
Patient identification 117 
All adult patients receiving antifungal therapy amphotericin B (liposomal and conventional), 118 
echinocandins, intravenous (IV) fluconazole, flucytosine or voriconazole) were identified through 119 
interrogation of pharmacy computer systems. Paediatric patients, those on standard oral 120 
prophylaxis (posaconazole and itraconazole) and outpatients (haematology day care unit attendees 121 
excepted) were excluded.  All patients identified were seen on a weekly stewardship ward round by 122 
an ID consultant and Antimicrobial Pharmacist, which incorporated reviewing medical notes, drug 123 
charts, laboratory tests and imaging. Cases are discussed with the clinical team whenever possible 124 
and recommendations for patient care documented in medical notes. 125 
 126 
Data collection and classification 127 
We prospectively recorded patient demographics; antifungal drug; indication for therapy 128 
(prophylaxis, empiric or targeted); site of infection; causative organism if identified; length of stay 129 
and in-hospital mortality into a Microsoft Excel (v2003) database. Recommendations made were 130 
also recorded and the antimicrobial pharmacist followed-up patients to assess implementation. 131 
 132 
Targeted therapy was defined as the administration of an antifungal drug by the treating clinicians to 133 
treat IFI suspected on the basis of typical symptoms, signs or results of laboratory tests or imaging. 134 
In neutropenic patients, empiric therapy was defined as antifungal drugs administered to febrile 135 
patients not responsive to broad-spectrum antibacterial therapy, without focal signs, symptoms or 136 
microbiological results suggestive of IFI. Pre-emptive therapy was not included as a category due to 137 
the lack of routine biomarker screening in at-risk patients. In non-neutropenic patients, empiric 138 
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therapy was defined as treatment initiated in critically ill patients with risk factors for invasive 139 
candidiasis in the absence of other known causes.  140 
  141 
Based on all results, the final diagnosis of IFI was classified by the stewardship team as ‘none’, 142 
‘prove ’, ‘probable’, or ‘possible’ IFI based on EORTC criteria.22 143 
 144 
Antifungal consumption and expenditure data 145 
Antifungal consumption data was extracted from Pharmacy records (JAC medicines management 146 
system v4.47) and reported as DDDs23 from 1st April 2009 to 30th September 2016. As the DDD for 147 
liposomal amphotericin (AmBisome®) has not been described, the average prescribed daily dose of 148 
200mg was used. Expenditure data is reported as cost of antifungals (in-patient and out-patient for 149 
all patient groups) issued from pharmacy per month, based on the price paid by St George’s hospital. 150 
To contextualise expenditure data, occupied bed days (OBD) data was obtained for the Trust as a 151 
whole and within the three Adult ICUs, as well as the numbers of chemotherapy cycles and bone 152 
marrow transplants performed in adults over the period 2009-16. 153 
 154 
Microbiologic Data 155 
Candidaemia speciation and susceptibility results from 2008-16 were extracted from the 156 
microbiology database. Speciation was by MALDI-TOF from 2012 and using the germ tube test and 157 
API Candida (Biomerieux) prior to 2012. Candida fluconazole MIC testing was performed using Etest 158 
(Biomerieux) locally and by the reference laboratory for all antifungals for significant isolates. 159 
Persistent candidaemia (same Candida species cultured from a blood sample taken ≤30 days of first 160 
in a given patient) was analysed as a single episode, whilst episodes >30 days apart were defined as 161 
a recurrence and counted as two episodes.   162 
 163 
Statistical Analysis 164 
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Data were analysed using Microscoft Excel v2003. Continuous variables were compared using the t-165 
test and categoric variables using the Chi square test in Prism v7 (GraphPad software, CA, USA).  166 
 167 
Results 168 
 169 
Between 6
th
 October 2010 and 30
th
 September 2016 there were 512 antifungal prescriptions which 170 
triggered a review by the stewardship team in 428 patients (an additional 4 patients were reviewed 171 
at the request of the clinical teams). 432 patients were reviewed 769 times on 246 AFS rounds 172 
(median 3 per round, range 1-10). Median patient age was 56 years (range 16-93); 58% were male. 173 
Top specialties prescribing antifungals were haemato-oncology (n=209, 40%), intensive care (n=49, 174 
11%: non-haemato-oncology patients only), general surgery (n=44, 9%), and infectious diseases 175 
(n=39, 8%). Two thirds of patients (n=285, 66%) were seen once; 16% (n=69) required 3 or more 176 
reviews (mainly those on targeted therapy). Seven patients died prior to review. 177 
 178 
Indication for and appropriateness of antifungal prescribing (table1 & figure 1) 179 
Of 516 antifungal prescribing episodes reviewed, the most common drug initiated was AmBisome® 180 
(181, 35%), followed by IV fluconazole (149,29%) and the echinocandins (120, 23%).  Of 212 patients 181 
receiving targeted therapy, 60% (n=127) had proven IFI on EORTC criteria and 75% (n=158) had 182 
either proven, probable (n=16) or possible (n=15) IFI. In 24 cases, therapy was targeted at a positive 183 
culture from a non-sterile site. These were classified as either non-invasive fungal infection (n=33) or 184 
fungal colonisation, usually respiratory (n=7). In 14 cases, patients with clinically significant 185 
infections failed to meet EORTC criteria.  186 
 187 
In the case of empiric prescribing, 82% (150/183) of patients were subsequently found to have no 188 
evidence of IFI on clinical, microbiologic and radiologic criteria. Only 21 patients (11%) subsequently 189 
met criteria for proven, probable or possible IFI. Of 121 patients receiving non-standard prophylaxis, 190 
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the majority (105, 87%) were haemato-oncology patients on primary prophylaxis (AmBisome® n=79; 191 
caspofungin n=25, micafungin n=1): 49 (47%) were deemed appropriate. Nine patients had 192 
antifungal prophylaxis switched or stopped prior to the AFS round. Switches in drug class (primarily 193 
to azoles) were recommended in 44 cases (AmBisome 28/79 and echinocandins 16/26) and stopping 194 
prophylaxis was recommended in 3 cases (2 caspofungin, 1 AmBisome). The most common 195 
indication for AmBisome was concomitant vincristine chemotherapy for ALL; for echinocandins it 196 
was adverse drug reactions. 197 
 198 
Stewardship advice and acceptance (Table 2) 199 
Advice was offered in two thirds of reviews (494/767, 64%), with 136 reviews resulting in multiple 200 
suggested interventions. Advice was followed in 84% of evaluable recommendations (471/558). The 201 
most common advice, switching to an alternative drug (n=122, 21%), had the lowest acceptance rate 202 
(85/118, 71%). Advice to stop antifungals (n=85), define treatment duration (n=71) or perform TDM 203 
(n=68) was also common with high acceptance rates (89%, 86%, and 83% respectively, table 2).  204 
 205 
The remaining 265 reviews required no intervention: 126 were on appropriate treatment, 57 were 206 
on prophylaxis as per Trust policy (where azoles were contraindicated), and 82 patients had already 207 
had their antifungal therapy modified prior to the round (stopped in 55, switched in 27). 208 
 209 
62% (86/138) of patients prescribed empiric antifungal therapy who had no IFI had their 210 
prescriptions stopped within one week, compared to 44 % (8/18) in our pre-implementation 2009 211 
audit (p=0.15). De-escalation was performed where appropriate in 87% (26/30) compared to 50% 212 
(2/4) of patients pre-implementation (p=0.004). TDM was performed where indicated by Trust 213 
guidelines in 74% (51/69) versus 43% (10/23) of patients (p=0.008) and results outside the 214 
therapeutic range acted upon in 74% (14/19) of cases (0/2 pre-intervention). 215 
 216 
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Microbiologic and clinical outcomes (Table 3) 217 
There were 131 proven IFIs. Microbiologically proven IFIs were diagnosed from blood (n=63) and 218 
other sterile sites (n=58).  Nine IFIs were diagnosed on histology only, and one by cryptococcal 219 
antigen in CSF. Candida albicans was the most commonly isolated pathogen, both from blood and 220 
other sterile sites (n=58, 44%), followed by non-albicans Candida sp. (n=44, 33%). The abdomen was 221 
the most common site of infection (40/102). Proven mould infection was rare (n=13): 2 cases of 222 
invasive aspergillosis proven on culture only (prosthetic joint infection and discitis), 4 cases of 223 
aspergillosis and 1 of mucormycosis proven microbiologically and histologically; 4 cases of invasive 224 
aspergillosis and 2 cases of mucormycosis diagnosed on histology alone. 225 
 226 
Figure 2 illustrates the number of candidaemia episodes and causative species distribution in adults 227 
and children during the pre- and post-AFS intervention period. Overall candidaemia numbers 228 
remained below the pre-intervention baseline of 30 per year. The proportion of Candidaemias due 229 
to non-albicans species was similar pre- and post-intervention: 27% and 45% in the 2 years 230 
preceding the intervention, and averaged 49% from 2010-2016 (range 33-70%). In terms of 231 
susceptibility of C glabrata to echinocandins, mode MIC for 34 isolates tested at the reference 232 
laboratory between 2009 and 2016 was 0.125 (susceptible) for each 2-year period except for 2015-233 
16 when it was 0.25 (intermediate), with no instances of echinocandin resistance to date. There 234 
were no reported candidaemia episodes due to C. krusei. 235 
 236 
Over 2010-16, 756 galactomannan (GM) tests were requested and sent away to the Reference 237 
laboratory, with a median(IQR) turnaround time (TAT) to result authorisation of 13 (11-17) days. As a 238 
result of the intervention, the number of GM tests increased from a baseline of 45 (2010) to 182 in 239 
2016, increasing spend from £2025 to £8190 (total cost 2010-16, £34,020). Beta-D-glucan was less 240 
frequently requested with 37 tests sent away over 6 years (cost £2183) with a similarly long TAT 241 
(median 12, IQR 9-14). For TDM tests, we were able to obtain data on the number and costs of tests 242 
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done in 2015-17: 192, 301 and 112 tests respectively, costing £26,600 total, mean annual spend 243 
£8867. Extrapolating the latter figure to the period 2010-16, the estimated mean annual laboratory 244 
spend was £14,900. 245 
 246 
Inpatient mortality (excluding patients on prophylaxis) was 27% (101/383), compared to 38% (19/50, 247 
p=0.1) in the pre-intervention period. In the prospective cohort, mortality was similar in patients 248 
with proven/ probable IFI compared to those without (42/150, 28% versus 61/231, 26%, p=0.7). 249 
Length of stay (LOS, median 34d, range 1-315d) did not alter significantly over the course of the 250 
intervention (28d years 1 and year 6, peak 37d in year 3). LOS was significantly higher for those with 251 
proven or probable IFI (47d versus 30d, p<0.0001). 252 
 253 
Antifungal spend and consumption (Figure 3a & 3b) 254 
Following implementation of our AFS program, total antifungal expenditure (adult and paediatric, 255 
inpatient and outpatient) initially showed a downward trend reducing by 26% in the first 3 years 256 
(from £0.98 million to £0.73 million). Expenditure then rose to between £1.17-1.4 million p.a.:  a 257 
20% increase compared to pre-intervention (2009/10). By comparison, NHS England data (P. 258 
Howard, NHS Improvement, personal communication) shows that national antifungal expenditure 259 
more than doubled from £37.8 million to £79.9 million during the 5 year period 2011-16.  260 
 261 
Independent of the AFS program, changes in drug pricing impacted expenditure; anidulafungin was 262 
added to formulary in April 2011 as the echinocandin of choice in non-haemato-oncology patients 263 
(28% reduction in price compared to caspofungin), posaconazole tablets were introduced in October 264 
2014 (cost neutral compared to liquid) and micafungin became the echinocandin of choice for all 265 
patients in October 2015 (cost neutral compared to anidulafungin, 28% reduction in price compared 266 
to caspofungin) with a further 38% price reduction in October 2016. 267 
 268 
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Parallel to the changes in expenditure, antifungal consumption initially decreased from 30,000 DDDs 269 
in 2009/10 to 22,103 in 2011/12 (a 26% reduction) before steadily increasing to 33,610 DDDs in 270 
2016/17. All antifungal drugs followed a similar trend. Posaconazole consumption showed the 271 
largest increase from from 499 DDDs in 2010/11 (2.1% of total antifungal consumption) to 4907 272 
DDDs (14.6% of total) following the introduction of posaconazole tablets to the formulary in October 273 
2015.  In 2016/17, liposomal amphotericin, itraconazole, flucytosine, and the echinocandins 274 
remained at lower usage compared to 2009/10, with voriconazole and fluconazole at a higher 275 
consumption compared to pre-intervention. The proportion of DDDs administered intravenously has 276 
reduced from 14% pre-intervention to 10% post-intervention as patients are switched from broad-277 
spectrum intravenous antifungals to oral azole therapy.  278 
 279 
Whilst occupied bed days (OBDs) remained constant within the Trust during the study period, 280 
numbers of patients at risk of IFI rose: admission to the adult ITUs increased substantially (33% 281 
increase from 3639 admissions in 2009 to 4828 in 2016) as did ITU-OBDs (41% increase in OBDs from 282 
12113 to 17079 over the same period). A similar increase was seen in the number of adult stem cell 283 
transplants with 29 transplants undertaken in 2009, rising to 53 in 2016. Figures for patients 284 
receiving courses of chemotherapy for haematological malignancy (data available from 2012/13) 285 
show a 20% increase from 233 in 2012/13 to 280 in 2013/14, remaining stable since.  286 
 287 
Discussion 288 
 289 
To the best of our knowledge, this is the most comprehensive evaluation of an antifungal 290 
stewardship programme to date, providing 6 years’ data on stewardship activities alongside clinical 291 
and financial outcomes. Our findings demonstrate that an antifungal stewardship programme has 292 
the potential to contain antifungal use and expenditure without adversely affecting patient 293 
outcomes, despite increasing numbers of “at risk” patients.   294 
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 295 
Our evaluation was based on reviews of over 400 adult patients, including 131 cases of proven IFI. 296 
Over half (51%) of patients belonged to the ‘high risk’ specialities of Haematology and Intensive 297 
Care, representative of a tertiary referral hospital population. Clinical management advice aside, the 298 
scope for intervention to stop or limit inappropriate prescribing was high, particularly in those on 299 
empiric therapy (82% with no IFI). For Haematology patients on prophylaxis, a class switch from high 300 
cost intravenous antifungals to azoles was recommended in 44/105 (42%) of reviews. Compared to 301 
the small pre-intervention audit, significant improvements were demonstrated with respect to de-302 
escalation and stopping in those without IFI, and performance of TDM.  303 
 304 
In its first three years, the St George’s AFS program substantially reduced annual antifungal spend 305 
(>£300K, a 30% decrease from baseline). Since 2014, spend has increased, with expenditure reaching 306 
£1.2 million in 2016/17 (20% higher than 2009/10). Inflation notwithstanding, this rise is modest 307 
compared to UK-wide expenditure which more than doubled over the same timeframe. Moreover, 308 
this occurred in the context of increasing numbers of patients at risk of IFI in the organisation during 309 
this period, with a 40% expansion of OBDs in Intensive Care, an 85% increase in stem cell transplants 310 
and a 20% increase in chemotherapy courses administered over this period.  These figures 311 
demonstrate the importance of incorporating denominator data as a surrogate for numbers of ‘at 312 
risk’ patients in comparisons of antifungal spend either longitudinally or b tween hospitals. 313 
Unsurprisingly, stewardship resulted in more laboratory tests and increased expenditure on this, 314 
however the mean annual expenditure of £14,900 is outweighed by the savings made on antifungal 315 
drugs.  316 
 317 
In the published literature, we found relatively few articles describing the implementation and 318 
impact of AFS programs, often limited to specific settings (Haematology
17
 or Intensive care
24
) or 319 
infection types (invasive candidiasis)14,16 rather than encompassing a hospital-wide approach. Only 320 
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three papers from France, Spain and the UK describe comprehensive programs similar to ours, 321 
directed at treatment of all IFIs and selected prophylaxis,15,18,20 of which just two employ the “gold 322 
standard” multidisciplinary approach with stewardship rounds as their core component.15,20 Our 323 
program is unique amongst the published literature in reporting on all 6 suggested performance 324 
measures:  antifungal expenditure and usage, adherence to therapeutic advice, mortality, incidence 325 
of IFI and quality of care (length of stay).
25
 326 
 327 
The Spanish program achieved a comparable reduction in overall antifungal consumption over 3 328 
years (20% versus 26%) and a cost saving of a similar order of magnitude to ours (US$370,682 over 329 
12-months18 versus £330,000 (US$450,000) over 3 years in our program. The other hospital-wide 330 
program reported from a tertiary hospital in Cambridge, UK
20
 achieved a comparable percentage 331 
reduction in antifungal expenditure over the first year (9.8% versus 11%), on a background of a 332 
higher baseline expenditure (£1,835,000 versus £928,000). Our intervention rate was higher overall 333 
than the French program (68% versus 54%), but similar to that in the Cambridge program (72%) and 334 
was sustained across the 6-year program with consistently high acceptance rates (>80% each year). 335 
 336 
Our study has several limitations. This was a single-centre study and the results may not be 337 
generalizable to hospitals with a different case mix. Adverse effects of antifungals and re-admission 338 
rates were not assessed. The only costs analysed were drug costs – we did not account for costs of 339 
laboratory diagnostics or hospital stay- although the median length of stay did not change over time. 340 
Whilst mortality in patients reviewed remained stable and appeared lower than in the pre-341 
intervention audit, the observational nature of our study precludes an assessment of the impact of 342 
our AFS program on mortality attributable to IFI. We did not formally assess the costs of the 343 
stewardship program; however it typically took 3 hours of antimicrobial pharmacist time and 2 hours 344 
of ID consultant time per week. 345 
 346 
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Key challenges for any stewardship program are delays in reviewing patients due to frequency of 347 
ward rounds, currently only weekly, and access to timely diagnostic results. Despite being a large 348 
teaching hospital with a sizeable at risk population, to date the fungal biomarkers galactomannan 349 
and beta-D-glucan, fungal PCR and candida susceptibility testing (excluding fluconazole) are sent 350 
away to the National Reference laboratory, with a median TAT of just under two weeks for GM and 351 
BDG. Whilst we have access to same-day radiological investigations (high resolution CT chest), 352 
bronchoscopy and BAL for high-risk patients is only available weekly for non-ITU patients. All of 353 
these factors limit our opportunity to impact on prescribing decisions in real time, particularly 354 
stopping unnecessary empiric therapy. There is clear scope to improve on the proportion of our 355 
patients with no evidence of IFI who had their antifungals stopped within a week (62%).  We are 356 
currently piloting the impact on antifungal prescribing of introducing beta-D-glucan testing in 357 
patients at risk of Invasive candidiasis on Intensive Care; in particular its impact on curtailing empiric 358 
echinocandin therapy in those without IFI. Of note, non-availability of rapid diagnostics and lack of 359 
resources (staff time) were two of the most frequent factors highlighted as a barrier to AFS in the 360 
recent English survey.
7
 361 
 362 
The need for antifungal stewardship is more pressing than ever as antifungal resistance emerges as a 363 
significant threat
13
 with outbreaks of Candida auris, and increasing reports of multi-drug resistant C. 364 
glabrata and azole-resistant Aspergillus spp.12 The recently updated IDSA guidelines on antibiotic 365 
stewardship for the first time suggest implementation of interventions to improve the appropriate 366 
prescribing of antifungal treatment, advising that antibiotic stewards must develop expertise in 367 
antifungal therapy and fungal diagnostics for programs to be successful.
26
 AFS also represents a 368 
significant opportunity to reduce unnecessary expenditure on high cost medicines in austerity 369 
measures within the UK National Health Service.  In England the majority of antifungal costs are not 370 
included within in-patient tariffs, so are paid for by NHS England, with currently few incentives to 371 
encourage individual hospitals to prioritise this issue. This was confirmed by a recent survey of 372 
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English Acute Hospital Trusts (n=47 responses), revealing that whilst 98% of Trusts had antimicrobial 373 
stewardship programs, only 5 (11%) had a dedicated AFS program,7 illustrating an important gap 374 
that the NHS England Improving Value Project27 seeks to address by introduction of financial 375 
incentives for implementation of AFS. 376 
 377 
In summary, we demonstrate that an antifungal stewardship program is readily implementable and 378 
sustainable over 6 years, offering high scope for targeted intervention to prevent unnecessary 379 
prescribing, with good clinician acceptance and no compromise to clinical outcomes. Containment of 380 
expenditure compared to the national picture and in the face of rising ‘at risk’ populations was 381 
possible using only 2-3 hours of Consultant and Senior Pharmacist time each week. Future 382 
challenges for antifungal stewardship programs such as ours include lack of access to rapid 383 
turnaround, accurate ‘rule out’ diagnostics.  Globally, antifungal stewardship remains a poor relation 384 
of antibiotic stewardship programs. To contain rising costs and the emergence of antifungal 385 
resistance, national initiatives are urgently needed to harmonise laboratory diagnostics in mycology 386 
and to encourage implementation of AFS by a greater proportion of English NHS hospitals.  387 
 388 
 389 
 390 
 391 
 392 
 393 
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 474 
Table 1. Antifungal drug, indication and final IFI classification 475 
 476 
Antifungal drug prescribed  
AmBisome 181 
Fluconazole 149 
Caspofungin   61 
Anidulafungin   56 
Voriconazole   43 
Micafungin      3 
Itraconazole a     2 
Not on treatment a     2 
Combination therapy    19  
 
(l-AMB + 5FC 7, l-AMB + MFG 1, l-
AMB + VRC 2, FLC + 5FC 1, AFG + 
VRC 4, cAMB + 5FC 4) 
 
 477 
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Figure 1: Final IFI diagnosis by indication for antifungal prescribing  479 
Total n=183 Empiric; 211 Targeted; 121 Prophylaxis 480 
 481 
 482 
*Non-invasive fungal infection not meeting EORTC criteria: 4 candida endopthalmitis diagnosed by ophthalmology, 2 mediastinitis post 483 
oesophageal perforation, 8 candiduria with prosthetic material in situ, 2 mastoid osteomyelitis with Aspergillus from ear swab, 4 high risk 484 
patients empirically treated for IFI too unwell to undergo diagnostics (CT scan), 2 semi-invasive pulmonary aspergillosis, 2 penetrating 485 
wounds from tree branches  486 
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Table 2: AFS Advice and acceptance 488 
 489 
Advice Given Total Accepted n (%)a   
Switch to alternative drug 122 85/118 (72%) 
Stop 85 74/83 (89%) 
Duration recommended 71 53/63 (84%) 
TDM 68 53/64 (83%) 
Diagnostics 58 41/49 (84%) 
IV to PO switch (same drug) 36 31/35 (86%) 
Adjust dose 30 29/30 (97%) 
Other b   121 105/116 (91%) 
Total 591  471/558 (84%)  
a acceptance of advice is not reported in all cases, for example if TDM was advised but the drug treatment ceased before TDM was required, 490 
or if advice was given on management of potential ADRs that didn’t occur 491 
b Includes advice on concurrent antibacterial/antiviral therapy (n=33), managing adverse drug reactions (22) or interactions (3), monitoring 492 
response to therapy (17), adjunctive treatment advice (28), escalation/treatment plans (11), prophylaxis post treatment (5) and follow up post 493 
discharge (4) 494 
 495 
 496 
  497 
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Table 3. Organism, sample and source of infection in proven IFI 498 
Organism  
 (n) 
Samples 
(n) 
Source/ focus of Infection 
(n) 
C. albicans (59) 
Blood culture 
(25) 
Infective endocarditis (5), line (6), 
abdominal (2), urinary source (5), 
unknown (7), 
Pus/fluid (20) 
Abdominal (17), Endovascular graft 
infection (1), Pleural effusion post 
CABG (1), Renal abscess (1)  
CSF (1) Device-associated ventriculitis (1) 
Tissue (13) 
Abdominal (3), prosthetic joint (3), 
endovascular graft infection (3), 
mediastinitis (1), sternal wound 
infection (1), urinary tract (1), 
alveolar proteinosis, with  
underlying fungal infection (1) 
C. dublinensis (3) Blood culture 
(2) Abdominal (1), line (1) 
Pus/fluid (1) Abdominal (1) 
C. glabrata (25) 
Blood culture 
(21) 
Infective endocarditis (2), line (3), 
abdominal (6), urinary source (2), 
unknown (8) 
Pus/fluid (2) Abdominal (2) 
Tissue (2) Abdominal (1), mediastinitis (1) 
C. guilliermondii 
(1) Fluid (1) Abdominal 
C. krusei (2) 
Fluid (2) Abdominal (1), unknown (1) 
C. lusitaniae (2) Blood culture 
(2) Abdominal (2) 
C. parapsilosis (4) Blood culture 
(3) 
abdominal (1), urinary source (1), 
unknown (1) 
Tissue (1) Endovascular infection 
C. tropicalis (7) Blood culture 
(5) 
abdominal (1), line (1), unknown 2, 
urinary (1) 
Pus/fluid (2) CNS (1), Abdominal (1) 
Candida sp. (1) 
Pus 
Neurosurgical site infection (metal 
plate in situ)  
A. flavus (1) 
Tissue  Rhino-orbital/CNS  
A. fumigatus (5) 
Pus (1) CNS 
Tissue (4) 
prosthetic joint infection (1), 
CNS/rhino-orbital (2), discitis (1) 
Aspergillus sp (4) Tissue – 
histological 
diagnosis 
only (4) Lung (2), brain (1), lung + brain (1) 
Cryptococcus sp  
(10) 
Blood culture 
+ CSF (2) 
CNS 
Blood culture 
(2) 
CSF (4) 
Tissue (1) 
CRAG + (1) 
Histoplasma 
capsulatum (1) Tissue  Disseminated  
Lichtheimia 
corymbifera (1) Tissue  Rhino-orbital  
Saccharomyces 
cerevisiae (1) Tissue  
Mediastinitis post oesophageal 
perforation 
Trichosporon 
mucoides (1) Blood culture  Line 
Mucormycosis (2) 
Tissue  Abdominal (histological diagnosis) 
Unspeciated 
(fungal spores 
with inflammation 
on biopsy)  (1) Tissue  Skin  
 499 
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 500 
Figure 2. Numbers and species distribution of Candidaemia episodes at St George’s Hospital 2008-2017. Non-sp (n=1) was not speciated. 501 
 502 
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Figure 3. Total annual antifungal use (in- and outpatient, Adult and Paediatric) pre and post-implementation of antifungal stewardship 506 
program at St George’s NHS Trust by financial year, 2009-17.a) Total annual antifungal expenditure: solid bars show St George’s NHS 507 
spend (left Y axis) and solid line indicates spend in acute English NHS Trusts (right Y axis, source: NHS England; pre-2011 data not 508 
available) b) consumption of antifungal drugs (DDDs/1000 OBDs), by drug and total  509 
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